Updated guidelines for biomarker testing in colorectal carcinoma: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
Por:
Garcia-Alfonso, P, Garcia-Foncillas, J, Salazar, R, Perez-Segura, P, Garcia-Carbonero, R, Musulen-Palet, E, Cuatrecasas, M, Landolfi, S, Cajal, SRY and Navarro, S
Publicada:
1 abr 2015
Resumen:
Publication of this consensus statement is a joint initiative of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM), intended to revise and update the diagnostic and treatment recommendations published 2 years ago on biomarker use and the management of patients with colorectal carcinoma (CRC), thereby providing an opportunity to improve healthcare efficiency and resource use in these patients. This expert group recommends testing for KRAS and NRAS status in all patients with metastatic CRC being considered for anti-epidermal growth factor receptor (anti-EGFR) therapy, as this type of treatment should only be used in patients not harbouring mutations in these genes. In contrast, testing for BRAF, EGFR, PI3K and PTEN mutation status is not necessary for therapeutic decision making, so does not need to be done routinely.
Filiaciones:
Garcia-Alfonso, P:
Hosp Gen Univ Gregorio Maranon, Serv Oncol Med, Dept Med Oncol, Madrid 28007, Spain
Garcia-Foncillas, J:
Fdn Jimenez Diaz, Dept Med Oncol, E-28040 Madrid, Spain
Salazar, R:
ICO Hosp Duran & Reynals, Dept Med Oncol, Barcelona, Spain
Perez-Segura, P:
Hosp Clin Univ San Carlos, Dept Med Oncol, Madrid, Spain
Garcia-Carbonero, R:
Univ Seville, Dept Med Oncol, Hosp Univ Virgen del Rocio, Inst Biomed Sevilla HUVR,CSIC, Seville, Spain
:
Hosp Badalona Germans Trias & Pujol, Dept Pathol, Badalona, Spain
Cuatrecasas, M:
Hosp Clin Barcelona, Dept Pathol, Barcelona, Spain
Landolfi, S:
Hosp Univ Vall dHebron, Dept Pathol, Barcelona, Spain
Cajal, SRY:
Hosp Univ Vall dHebron, Dept Pathol, Barcelona, Spain
Navarro, S:
Hosp Clin Univ Valencia, Dept Pathol, Valencia, Spain
|